论文部分内容阅读
胰腺导管腺癌(PDAC)是较为致命的癌症之一，总体5年存活率不到5%。该病通常诊断为晚期，治疗手段有限。随着分子生物学的发展，肿瘤的靶向治疗针对性强，精准度高，效果显著。因此，挖掘理想的靶点是PDAC靶向治疗的关键，有助于进一步提高对本病的诊断和治疗水平。与其他肿瘤相比，PDAC促纤维结缔组织增生的改变更为明显，对传统治疗表现出明显的耐药性，并具有高度免疫抑制的肿瘤微环境。本研究讨论了在PDAC中成纤维细胞活化蛋白(FAP)与miR-30a-5p的一些新发现，即FAP、miR-30a-5p对PDAC主要生物学功能的影响及两者之间的相互关系，并指出未来研究的发展方向，为PDAC的靶向治疗提供新的思路。“,”Pancreatic ductal adenocarcinoma (PDAC) is one of the most deadly cancers, with an overall five-year survival rate of less than 5%. The disease is often diagnosed at an advanced stage with limited treatment options. With the development of molecular biology, tumor targeted therapy is highly targeted, precise and effective. Therefore, to explore the ideal target is the key to PDAC targeted therapy, which is helpful to further improve the level of diagnosis and treatment of this disease. Compared with other tumors, PDAC showed more significant fibrotic changes, showed significant resistance to traditional therapies, and had a highly immunosuppressive tumor microenvironment. This study discussed some new findings of PDAC, that is to say, fibroblast activated protein and miR-30a-5p on the main biological functions of PDAC, the effects and the relationship between them. It also pointed out the development direction of future studies, so as to provide a new idea for PDAC targeted therapy.